Cipla Receives FDA’s ANDA Approval for its HFA Inhalation Aerosol to Treat Acute Episodes of Bronchospasm or to Prevent Asthmatic Symptoms

 Cipla Receives FDA’s ANDA Approval for its HFA Inhalation Aerosol to Treat Acute Episodes of Bronchospasm or to Prevent Asthmatic Symptoms

Cipla to Acquire Venus Remedies’ Elores to Strengthen its Critical Care Footprints in India

Shots:

  • Cipla’s Albuterol Sulfate Inhalation Aerosol 90mcg (base)/actuation is first device-based metered dose inhaler receives approval in the US which will further strengthen Cipla’s footprints in the US
  • The first AB-rated generic version of Merck’s Proventil HFA Inhalation Aerosol is targeted to treat acute episodes of bronchospasm or prevention of asthmatic symptoms
  • In end of Feb 2020, Proventil HFA Inhalation Aerosol had sales of $2.8B for 12-month period from Feb 2019. Additionally, the company is also planning to donate the product for meeting end to end ne

Click here ­to­ read full press release/ article | Ref: Cipla | Image: Cipla

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post